Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Post-Shutdown ANDA Bolus Could Be Massive

Executive Summary

More than 300 generic drug applications might be officially filed when the shutdown ends, substantially increasing stress on assessors and other Office of Generic Drugs staff.

You may also be interested in...



US FDA Appears To Have Avoided Shutdown-Related ANDA Bolus

Generic submissions were below historical norms in December and modestly higher January, meaning shutdown likely did not create a large pile of pending work.

ANDA Review: Moving From Tentative To Final Approval Could Require 10 Months Or More

US FDA draft guidance says substantive changes to reference product may require major ANDA amendment and 10-month review goal for the generic.

Shutdown Deal Avoids Further US FDA Service Cuts, But Damage May Linger

Employees are no doubt are excited to resume work and may have a dozen or more major NDAs pending, but agency morale may not recover quickly.

Related Content

Topics

UsernamePublicRestriction

Register

PS124639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel